Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs YOURx Health
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · YOURx Health: Check date not recorded
vs
Verdict66/ 100
Grade C · #267YOURx Health
YOURx Health is a compounded GLP-1 telehealth platform powered by the MD Integrations provider network.
Visit YOURx HealthThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 66/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. YOURx Health still earns its place — shoppers who want mD Integrations-network GLP-1 with included lab monitoring.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results65
92
Real-world results65
97Price honesty74
97
Price honesty74
96Prescriber access41
96
Prescriber access41
88Formulary choice88
88
Formulary choice88
95Cancellation fairness56
95
Cancellation fairness56
93Member support74
93
Member support74
Price, coverage & features
| Metric | CoreAge Rx | YOURx Health |
|---|---|---|
| Verdict Score | 94/100 | 66/100 |
| Grade | A | C |
| Semaglutide | $99/mo | From $179/mo (compounded) |
| Tirzepatide | $149/mo | From $199/mo (compounded) |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
YOURx Health
What we like
- Lab monitoring included (per the home page) — most peer platforms gate labs as add-ons or skip them entirely
- Physician video consultation with 'board-certified provider' disclosed
- MD Integrations network is a recognized white-label clinical platform
- Transparent published pricing: semaglutide injection $179/mo, tirzepatide injection $199/mo, oral RDT tablets $159-$179/mo
The caveats
- Parent company / legal entity name NOT publicly disclosed — a material transparency gap for a health purchase
- NO LegitScript / NABP / PCAB / BBB seal displayed — material trust-signal gap vs peer platforms
- Per-state availability shown as 'Coverage 0 States' (placeholder metric) — appears the home page is incomplete or the platform is pre-launch
- Pharmacy partners NOT publicly named
- Too little is published about it to judge — treat this listing as provisional
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want mD Integrations-network GLP-1 with included lab monitoring.
Visit YOURx Health Read the full YOURx Health review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for YOURx Health does the reverse.
More on CoreAge Rx
More on YOURx Health
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.